Aarhus University Hospital
Aarhus, 8200, Denmark
NCT Number: NCT06318299
It is well established that the brain is capable of consuming ketone bodies, especially during low glucose availability, e.g. fasting. Cerebral metabolism of ketone bodies depends on passage of the blood brain barrier and especially the global blood concentration of ketone bodies.
Ketone bodies can be administered exogenously, and the most commonly used in clinical trials is 3-hydroxybutyrate (3-OHB). 3-OHB is carried by simple diffusion and facilitated diffusion through several monocarboxylic acid transporters (MCTs) across the blood-brain barrier.
To our knowledge, no studies in human adults exist that concurrently measure 3-OHB concentrations in blood and cerebrospinal fluid (CSF) after ingestion or infusion of exogenous ketone supplementation, necessitating further study.
Aims:
* The 3-OHB CSF/blood ratio after oral ingestion of 30 g ketone ester - primary endpoint * The window of effect: Ketone supplementation 1 h or 2 h before CSF sampling * If concentration measurements by point-of-care testing are non-inferior to mass spectrometry * If acute 3-OHB ingestion increases plasma brain-derived neurotrophic factor (BDNF) levels
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Not applicable
Aarhus, 8200, Denmark
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Commercially available ketone ester drink (KetoneAid, Virginia, USA)
Taste and appearance matched noncaloric placebo drink
Time frame: 1-2 hours after ingestion
After oral ingestion of 30 g ketone ester drink or placebo drink
Time frame: 1-2 hours after ingestion
After oral ingestion of 30 g ketone ester drink or placebo drink, Point-of-care testing (POCT)
Time frame: 1-2 hours after ingestion
After oral ingestion of 30 g ketone ester drink or placebo drink, Mass Spectrometry Detection
Time frame: 1-2 hours after ingestion
After oral ingestion of 30 g ketone ester drink or placebo drink
Time frame: 1-2 hours after ingestion
After oral ingestion of 30 g ketone ester drink or placebo drink, Point-of-care testing (POCT)
Time frame: 1-2 hours after ingestion
After oral ingestion of 30 g ketone ester drink or placebo drink, Mass Spectrometry Detection
Time frame: 1-2 hours after ingestion
After oral ingestion of 30 g ketone ester drink or placebo drink, Point-of-care testing (POCT)
Time frame: 1-2 hours after ingestion
After oral ingestion of 30 g ketone ester drink or placebo drink
Time frame: Before ingestion
Before oral ingestion of 30 g ketone ester drink or placebo drink, Point-of-care testing (POCT)
Time frame: Before ingestion
After oral ingestion of 30 g ketone ester drink or placebo drink, Mass Spectrometry Detection
Time frame: Before ingestion
Before oral ingestion of 30 g ketone ester drink or placebo drink, Point-of-care testing (POCT)
Time frame: Before ingestion
Before oral ingestion of 30 g ketone ester drink or placebo drink
University of Aarhus
Other
Acronym: KetoBrain
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06320522
Acid-Base Imbalance, Acidosis
Oxford, Oxfordshire, United Kingdom
View Trial DetailsNCT06053138
Acid-Base Imbalance, Acidosis
Viborg, Denmark
View Trial DetailsNCT06769100
Acid-Base Imbalance, Acidosis
Montreal, Quebec, Canada
View Trial DetailsNCT06418074
Acid-Base Imbalance, Acidosis
Herning, Denmark
View Trial Details